Ginkgo Bioworks Holdings Inc vs iShares MSCI Taiwan ETF — how do they compare? Ginkgo Bioworks Holdings Inc trades at $9.06 (market cap $590.53M), while iShares MSCI Taiwan ETF trades at $102.43. The key difference: iShares MSCI Taiwan ETF is trading nearer its 52-week high, Ginkgo Bioworks Holdings Inc nearer its low. Which is the better fit depends on your goals.
| DNA | EWT | |
|---|---|---|
Market Cap | $590.53M | — |
Sector | Health | Broad Market / Factor |
52-Week High | $16.14 | $111.53 |
52-Week Low | $5.48 | $58.05 |
Enterprise Value | $627.78M | — |
Signals from Pluang's Aura AI — not financial advice
DNA trades at $9.05, down 0.44% on the day, reflecting ongoing investor caution. The technical outlook is bearish, while fundamentals show significant losses with a net income margin of -201.05% and negative cash flows. Recent earnings have been mixed, missing estimates in two of the last three quarters. Analyst sentiment is divided, with a slight lean toward buy ratings amid high volatility and operational challenges.
The outlook remains challenging due to persistent losses and cash burn, though analyst coverage suggests potential long-term value. Key risks include execution missteps and intense competition in biotechnology. Investment appeal hinges on future profitability improvements and successful business model execution.
EWT, the iShares MSCI Taiwan ETF, trades at $101.88, down 4.04% on the day amid a bearish technical signal. The ETF has delivered strong returns in 2026, more than doubling from its 2025 close, driven by Taiwan's critical role in the global semiconductor and AI supply chain. However, key financial ratios are unavailable, and the technical outlook is mixed, with moving averages bullish but oscillators neutral.
The outlook for EWT is clouded by geopolitical tensions with China and potential currency volatility, though its exposure to the AI-driven semiconductor boom offers significant growth potential. Investors face a trade-off between high-reward tech exposure and substantial geopolitical risk, with the current price near key support levels suggesting a cautious near-term stance is warranted.
Trailing returns across standard periods
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →EWT tracks the MSCI Taiwan 25/50 Index, providing targeted exposure to large and mid-cap companies in Taiwan. It is heavily concentrated in the information technology sector, serving as a liquid instrument for investors seeking a single-country view of Taiwan's export-oriented and tech-driven economy.
Read more on EWT →